This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462
(also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu)
vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in
participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior
exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens
and to select the recommended dose of the combination for phase III. Towards that end,
the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from
participants randomized in the study will be evaluated.
Additional locations may be listed on ClinicalTrials.gov for NCT07047118.
Locations matching your search criteria
United States
New York
New York
Laura and Isaac Perlmutter Cancer Center at NYU LangoneStatus: Active
Name Not Available
The study consists of a screening period, a randomization period, a treatment period, a
post-treatment safety follow-up followed by a long-term follow-up period.
JSB462 administration starts at day 1 of randomization, whereas AAA617 administration
starts at day 1 of treatment period. Participants in arm 1 and arm 2 will therefore
receive JSB462 during the 14-day randomization period before first administration of
AAA617.
- JSB462 is administered orally, daily and continuously (100 mg or 300 mg once a day
(QD)) until disease progression per Prostate Cancer Working Group (PCWG) 3-modified
Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as assessed by the
investigator, the occurrence of unacceptable toxicities, death, participant decision
or investigator decision.
- AAA617 will be administered at 7.4 gigabecquerel (GBq) intravenously every 6 weeks
for up to 6 doses, unless there is disease progression per PCWG3-modified RECIST
v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities,
death, participant decision or investigator decision.
During the post-treatment follow up period:
- Safety follow-Up: After discontinuation of study treatment, all participants will be
followed for at least 1 safety follow-up visit (30 days [+/- 7 days] after end of
treatment visit). Subsequent lines of therapy may be administered according to
investigator's discretion after treatment discontinuation.
- Long-term follow-up: Starts after the Safety follow-up period and lasts until the
end of study. Safety, efficacy and survival information may be collected from the
participants during this period.
Lead OrganizationNovartis Pharmaceuticals Corporation
